Masoud Shamaei

Masoud Shamaei

Auto-generated profile, based on publicly available information

Masoud Shamaei

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in Human Immunology
Verified
Journal Article
Closed access
PDF file
MSMasoud Shamaei
Masoud Shamaei
EMEsmaeil Mortaz
Esmaeil Mortaz
MPMihan Pourabdollah
Mihan Pourabdollah
JGjohan Garssen
johan Garssen
PTPayam Tabarsi
Payam Tabarsi
IAIan Adcock
Ian Adcock

15 July 2021 in Infection and Immunity
Verified
Journal Article
Closed access
MSMasoud Shamaei
Masoud Shamaei
MMMehdi Mirsaeidi
Mehdi Mirsaeidi
Although nontuberculous mycobacteria (NTM) are considered opportunistic infections, incidence and prevalence of NTM infection are increasing worldwide becoming a major public health threat. Innate immunity plays an essential role in mediating the initial host response against these intracellular bacteria. Specifically, macrophages phagocytose and eliminate NTM and act as antigen-presenting cells, which trigger downstream activation of cellular and humoral adaptive immune responses.

1 September 2009 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
MSMasoud Shamaei
Masoud Shamaei
MMMajid Marjani
Majid Marjani
ECEhsan Chitsaz
Ehsan Chitsaz
MKMehdi Kazempour
Mehdi Kazempour
MEMehdi Esmaeili
Mehdi Esmaeili
AVAli A. Velayati
Ali A. Velayati

1 March 2011 in American Journal of Therapeutics
Verified
Journal Article
Closed access
PBParvaneh Baghaei
Parvaneh Baghaei
PTPayam Tabarsi
Payam Tabarsi
DDDonna Dorriz
Donna Dorriz
MMMajid Marjani
Majid Marjani
MSMasoud Shamaei
Masoud Shamaei
AVAliakbar Velayati
Aliakbar Velayati
Compared with the treatment of drug-sensitive tuberculosis, the treatment of multidrug-resistant tuberculosis (MDR-TB) is more difficult. This study was conducted at the national referral center of tuberculosis in Tehran, Iran, to evaluate adverse drug reactions of treatment of MDR-TB. From 2006 to 2009, all patients admitted into Masih Daneshvari Hospital in Tehran, Iran, for MDR-TB were considered for this study. The standard treatment for MDR-TB consisted of amikacin, prothionamide, ofloxacin, and cycloserine. Ethambutol and pyrazinamide were added to treatment if mycobacterium was sensitive to them. All adverse effects observed in patients were recorded in our registry. Eighty patients were considered in the study; of this cohort, 44 were male and 36 were female. The mean age of patients was 40.64 ± 17.53 years (range, 14-81 years). All patients received standardized therapy for MDR-TB. The major adverse effects included neurologic side effects (depression, convulsions, consciousness, psychosis, suicide; 7.5%), hepatitis (5%), rash (1.3%), renal toxicity (3.8%), and auditory toxicity (14.5%). Those with neurologic side effects had less favorable outcome (P value = 0.038) and risk of death was increased among them (odds ratio, 13.8; 95% confidence interval, 2.2-86.77). Other adverse effects did not show statistical significance in our analysis. A major adverse effect such as neurologic side effects (depression, convulsions, consciousness, and psychosis) can result in an increased chance of death among patients with MDR-TB.

9 November 2014 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
MPMihan Pourabdollah
Mihan Pourabdollah
MSMasoud Shamaei
Masoud Shamaei
SKShirin Karimi
Shirin Karimi
MKMahdi Karimi
Mahdi Karimi
AKArda Kiani
Arda Kiani
HJHamid Reza Jabbari
Hamid Reza Jabbari

5 July 2011 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
PBParvaneh Baghaei
Parvaneh Baghaei
PTPayam Tabarsi
Payam Tabarsi
PFParissa Farnia
Parissa Farnia
MMMajid Marjani
Majid Marjani
FSFatemeh Maryam Sheikholeslami
Fatemeh Maryam Sheikholeslami
AVAli Akbar Velayati
Ali Akbar Velayati
Introduction: Several species of non-tuberculosis mycobacteria (NTM) can affect humans and can cause either symptomatic or asymptomatic infection. This study aimed to determine the clinical and radiological manifestation, as well as the treatment, of M. simiae in patients in Masih Daneshvari Hospital, a TB referral hospital in Iran. Methodology: This retrospective study involved all patients presenting to our referral center from 2002 to 2009, with confirmation of M. simiae pulmonary infection. For all patients, sputum smear and culture for identification was performed, as was drug susceptibility testing. Additionally, PCR identification methods for NTM, and high-resolution CT scan were conducted. All patients were treated according to American Thoracic Society recommendations.Results: In total, 26 cases of M. simiae were identified in our center. The mean age of the patients was 58.23 ± 16.9years. Only one patient was HIV positive, and all but one were Iranian. The most frequent symptom was coughing (92.3%), and 100% of the patients had nodular lesions. In addition, bronchiectasis and cavitation were present in 84.6% and 88.5% respectively. All the patients were resistant to every first-line drug. Two patients failed the treatment, and twenty-four were cured, after which no recurrence of the disease was observed.Conclusion: M. simiae may present with clinical and radiological manifestations consistent with tuberculosis, and be resistant to anti-TB agents. A more efficient treatment for NTMs such as M. simiae is needed, to shorten the period of treatment and proved fewer adverse effects than current therapies.